



# RYBREVANT<sup>®</sup>

(amivantamab)

## NOW APPROVED

for the treatment of patients with locally advanced or metastatic NSCLC with **activating EGFR Exon 20 insertion mutations** whose disease has progressed on or after platinum based chemotherapy<sup>1</sup>

**RYBREVANT<sup>®</sup> (amivantamab) achieved almost 2x longer OS** compared to real world anti cancer therapies<sup>2</sup>

Latest long term **efficacy outcomes of CHYSALIS** showed

Median OS  
**23**  
months<sup>3</sup>

**2 year landmark**  
OS rate of

**47%**<sup>3</sup>

**Consistent efficacy**  
regardless of prior  
therapy type<sup>3</sup>



**SCAN ME**

For latest approved  
**RYBREVANT<sup>®</sup>**  
prescribing information

**Abbreviations:**  
NSCLC: non-small-cell lung cancer; EGFR: epidermal growth factor receptor;  
OS: overall survival

**References:**  
1. Singapore RYBREVANT<sup>®</sup> Prescribing Information - Approved 28 April 2023  
2. Girard N, et al. Poster presented at ELCC 2023; abstract 422.  
3. Garrido P, et al. Oral presented at ELCC 2023; abstract 779.

Janssen Oncology  
members of the Janssen Group